{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:01:11Z","timestamp":1763017271463},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/bmt.2013.37","type":"journal-article","created":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T10:41:42Z","timestamp":1364812902000},"page":"1179-1184","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"48","author":[{"given":"T","family":"Nishihori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Ochoa-Bayona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Shain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Baz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H S","family":"Jim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,1]]},"reference":[{"key":"BFbmt201337_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"S Kumar","year":"2008","unstructured":"Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516\u20132520.","journal-title":"Blood"},{"key":"BFbmt201337_CR2","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770\u20131781.","journal-title":"N Engl J Med"},{"key":"BFbmt201337_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929\u2013936.","journal-title":"J Clin Oncol"},{"key":"BFbmt201337_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","volume":"102","author":"P Corradini","year":"2003","unstructured":"Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927\u20131929.","journal-title":"Blood"},{"key":"BFbmt201337_CR5","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","volume":"109","author":"C Crawley","year":"2007","unstructured":"Crawley C, Iacobelli S, Bj\u00f6rkstrand B, Apperley J, Niederwieser D, Gahrton G . Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588\u20133594.","journal-title":"Blood"},{"key":"BFbmt201337_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: 1195\u20131203.","journal-title":"Lancet Oncol"},{"key":"BFbmt201337_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"P Richardson","year":"2010","unstructured":"Richardson P, Weller E, Lonial S, Jakubowiak A, Jagannath S, Raje N et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679\u2013686.","journal-title":"Blood"},{"key":"BFbmt201337_CR8","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","volume":"27","author":"AJ Jakubowiak","year":"2009","unstructured":"Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009; 27: 5015\u20135022.","journal-title":"J Clin Oncol"},{"key":"BFbmt201337_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"S Rajkumar","year":"2010","unstructured":"Rajkumar S, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29\u201337.","journal-title":"Lancet Oncol"},{"key":"BFbmt201337_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110\u20131120.","journal-title":"N Engl J Med"},{"key":"BFbmt201337_CR11","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","volume":"112","author":"L Rosi\u00f1ol","year":"2008","unstructured":"Rosi\u00f1ol L, P\u00e9rez-Sim\u00f3n JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591\u20133593.","journal-title":"Blood"},{"key":"BFbmt201337_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbmt.2008.10.030","volume":"15","author":"DH Vesole","year":"2009","unstructured":"Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA et al. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant 2009; 15: 83\u201391.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201337_CR13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"G Tricot","year":"1996","unstructured":"Tricot G, Vesole D, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196\u20131198.","journal-title":"Blood"},{"key":"BFbmt201337_CR14","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","volume":"18","author":"G Martinelli","year":"2000","unstructured":"Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18: 2273\u20132281.","journal-title":"J Clin Oncol"},{"key":"BFbmt201337_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V96.1.355","volume":"96","author":"M Cavo","year":"2000","unstructured":"Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355\u2013357.","journal-title":"Blood"},{"key":"BFbmt201337_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","volume":"19","author":"RP McQuellon","year":"1997","unstructured":"McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19: 357\u2013368.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201337_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"B Durie","year":"2006","unstructured":"Durie B, Harousseau J, Miguel J, Blad\u00e9 J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbmt201337_CR18","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201337_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201337_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt201337_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFbmt201337_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","volume":"113","author":"G Gahrton","year":"2001","unstructured":"Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bj\u00f6rkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209\u2013216.","journal-title":"Br J Haematol"},{"key":"BFbmt201337_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","volume":"30","author":"S Giralt","year":"2002","unstructured":"Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367\u2013373.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201337_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","volume":"10","author":"N Kr\u00f6ger","year":"2004","unstructured":"Kr\u00f6ger N, Perez-Simon J, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698\u2013708.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201337_CR25","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","volume":"118","author":"S Kumar","year":"2011","unstructured":"Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011; 118: 1979\u20131988.","journal-title":"Blood"},{"key":"BFbmt201337_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","volume":"100","author":"N Kr\u00f6ger","year":"2002","unstructured":"Kr\u00f6ger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755\u2013760.","journal-title":"Blood"},{"key":"BFbmt201337_CR27","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"D Maloney","year":"2003","unstructured":"Maloney D, Molina A, Sahebi F, Stockerl-Goldstein K, Sandmaier B, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447\u20133454.","journal-title":"Blood"},{"key":"BFbmt201337_CR28","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","volume":"29","author":"B Bj\u00f6rkstrand","year":"2011","unstructured":"Bj\u00f6rkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016\u20133022.","journal-title":"J Clin Oncol"},{"key":"BFbmt201337_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BFbmt201337_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt201337_CR31","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"J Harousseau","year":"2009","unstructured":"Harousseau J, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood 2009; 114: 3139\u20133146.","journal-title":"Blood"},{"key":"BFbmt201337_CR32","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.bbmt.2012.04.001","volume":"18","author":"JM Preussler","year":"2012","unstructured":"Preussler JM, Denzen EM, Majhail NS . Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1620\u20131628.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201337_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/bmt.2012.133","volume":"48","author":"NS Majhail","year":"2012","unstructured":"Majhail NS, Mau LW, Denzen EM, Arneson TJ . Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database. Bone Marrow Transplant 2012; 48: 294\u2013300.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201337_CR34","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","volume":"28","author":"H Lokhorst","year":"2010","unstructured":"Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, P\u00e9rez-Simon JA et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28: 4521\u20134530.","journal-title":"J Clin Oncol"},{"key":"BFbmt201337_CR35","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","volume":"118","author":"E Kneppers","year":"2011","unstructured":"Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011; 118: 2413\u20132419.","journal-title":"Blood"},{"key":"BFbmt201337_CR36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","volume":"41","author":"C Wolschke","year":"2012","unstructured":"Wolschke C, St\u00fcbig T, Hegenbart U, Sch\u00f6nland S, Heinzelmann M, Hildebrandt Y et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study. Exp Hematol 2012; 41: 134\u2013142.","journal-title":"Exp Hematol"},{"key":"BFbmt201337_CR37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","volume":"17","author":"P Corradini","year":"1999","unstructured":"Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208\u2013215.","journal-title":"J Clin Oncol"},{"key":"BFbmt201337_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07992.x","volume":"148","author":"J Pidala","year":"2010","unstructured":"Pidala J, Anasetti C, Jim H . Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol 2010; 148: 373\u2013385.","journal-title":"Br J Haematol"},{"key":"BFbmt201337_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","volume":"15","author":"AC Sherman","year":"2009","unstructured":"Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ . Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 12\u201320.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201337","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:22:58Z","timestamp":1648056178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFbmt201337"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.37","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,1]]},"assertion":[{"value":"13 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MA is a consultant to and receives research support from Millennium Pharmaceuticals Inc.; RB, receives research support from Millennium Pharmaceuticals Inc. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}